Clinical trials are essential for getting new medicines approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies. The objective of a clinical trial is to determine the efficacy and safety of a new medicine.
We are conducting multiple clinical trials in a range of therapeutic areas. See below to learn more about our current clinical trials and to find out if you could be eligible to participate.
A phase 1 multi-country, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A1811 in HER2 expressing or mutated advanced malignant solid tumor subjects
NCT number:
NCT04446260
Recruiting
(US sites active)
Phase: 1
Status:
Actual Study Start Date:
September 3, 2020
Estimated Primary Completion Date:
December 2023
Estimated Study Completion Date:
December 2023
A multicenter, randomized, double-blind, placebo-controlled phase III study of fuzuloparib combined with abiraterone acetate and prednisone (AA-P) versus placebo combined with AA-P as first-line treatment in patients with metastatic castration-resistant prostate cancer
NCT number:
NCT04691804
Recruiting
(US sites active)
Phase: 3
Status:
Actual Study Start Date:
March 18, 2021
Estimated Primary Completion Date:
December 31, 2026
Estimated Study Completion Date:
December 31, 2026
A randomized, open-label, international, multi-center, phase 3 clinical study of PD-1 antibody SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC) who have not previously received systemic therapy
NCT number:
NCT03764293
Active, not recruiting
(US sites active)
Phase: 3
Status:
Actual Study Start Date:
June 10, 2019
Estimated Primary Completion Date:
December 2021
Estimated Study Completion Date:
June 2022
A randomized, double-blind, placebo-controlled, multicenter, two-stage phase Ⅲ study evaluating the efficacy and safety of hetrombopag olamine tablets in treatment of chemotherapy-induced thrombocytopenia
NCT number:
NCT05261646
Not yet recruiting
Phase: 3
Status:
Actual Study Start Date:
April 15, 2022
Estimated Primary Completion Date:
March 15, 2025
Estimated Study Completion Date:
December 15, 2025
Evaluation of the efficacy and safety of INS068 injection and insulin degludec subcutaneous injection once daily in subjects with type 2 diabetes mellitus not adequately controlled with one or two oral antidiabetics
NCT number:
NCT04663282
Active, not recruiting
(US sites active)
Phase: 2
Status:
Actual Study Start Date:
February 4, 2021
Estimated Primary Completion Date:
June 27, 2022
Estimated Study Completion Date:
June 27, 2022
Register to get the latest company news, updates, and information.
Stay tuned for future communications from Luzsana Biotechnology™.